Show simple item record

dc.contributor.authorBahadori, F.
dc.contributor.authorDemiray, M.
dc.date.accessioned2020-08-07T12:52:08Z
dc.date.available2020-08-07T12:52:08Z
dc.date.issued2018
dc.identifier10.1007/s12094-018-1854-z
dc.identifier.issn1699048X (ISSN)
dc.identifier.urihttp://hdl.handle.net/20.500.12498/2842
dc.description.abstractAlthough oxaliplatin (Oxali) plays a key role in the treatment of many types of cancer and has been reported to be an irritant, there is no specific and effective method for its extravasation and failure in Oxali extravasation management results in the need for plastic surgery. In the body, Oxali bio-transforms upon dilution in chloride-containing buffer salts to its di-chloro derivative and loses an oxalate molecule. Consequently, the chloride ions exchange with water molecules in the intracellular environment to produce the di-aqua derivative, which is the most active biotransformation product of Oxali in terms of forming the DNA adducts. Thus, inhibiting transformation of di-chloro to di-aqua derivatives by accumulating chloride ions at the site of extravasation and saturating the Oxali molecule with these ions is a strategy that could help manage extravasation. Injecting normal saline at this site is a simple yet effective way to achieve this goal. © 2018, Federación de Sociedades Españolas de Oncología (FESEO).
dc.language.isoEnglish
dc.publisherSpringer-Verlag Italia s.r.l.
dc.sourceClinical and Translational Oncology
dc.titleManagement of extravasation of oxaliplatin by mimicking its biotransformation
dc.typeArticle


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record